Glenmark Pharmaceuticals is currently trading at Rs. 648.10, up by 4.70 points or 0.73% from its previous closing of Rs. 643.40 on the BSE.
The scrip opened at Rs. 656.85 and has touched a high and low of Rs. 656.85 and Rs. 646.00 respectively.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 666.00 on 27-Aug-2018 and a 52 week low of Rs. 483.60 on 30-May-2018.
Last one week high and low of the scrip stood at Rs. 666.00 and Rs. 629.95 respectively. The current market cap of the company is Rs. 18154.70 crore.
The promoters holding in the company stood at 46.54%, while Institutions and Non-Institutions held 37.55% and 15.91% respectively.
Glenmark Pharmaceuticals’ subsidiary -- Glenmark Pharmaceuticals Europe has entered into a strategic, exclusive licensing agreement for marketing generic Tiotropium Bromide dry powder inhaler (DPI) in Western Europe.
Tiotropium Bromide DPI is a generic version of Boehringer Ingelheim’s Spiriva Handihaler. The product is used in the treatment of chronic obstructive pulmonary disease (COPD). This is the second inhalation product in-licensed by Glenmark for the European market after Fluticasone/Salmeterol dry powder inhaler.
According to data from IQVIA, Boehringer Ingelheim’s Spiriva Handihaler recorded sales of $724 million in the EU in the 12 month period ended March 2018.
Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).
